Intravenous administration of lisuride in the treatment of neuroleptic malignant syndrome.
The neuroleptic malignant syndrome (NMS) is a very rare but life-threatening complication of neuroleptic treatment. The mortality of NMS has been estimated at 8-30% and the most common cause of death is respiratory failure. Signs and symptoms of NMS are attributed to impairment of dopaminergic neurotransmission in the central nervous system. We describe two cases of NMS successfully treated with intravenous lisuride in combination with oral L-Dopa.
Institute of Neurology, University of Bari, Italy.
M
M
de Mari
P
P
Lamberti
F
F
Simone
G
G
Iliceto
F
F
Federico
E
E
Ferrari
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001833:Body Temperature Regulation / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage*; D008090:Lisuride / Q000008:administration & dosage*; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy*; D011595:Psychomotor Agitation / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy*
D014150:Antipsychotic Agents; D007980:Levodopa; D008090:Lisuride